甲状腺癌的基因治疗

郑薇; 谭建

甲状腺癌的基因治疗

郑薇 , 谭建

文章导航 > 国际放射医学核医学杂志 > 2007, 31 > 4: (197-201)

引用本文:

Citation:

甲状腺癌的基因治疗

郑薇,
谭建

300052 天津, 天津医科大学总医院核医学科
中图分类号: R730.54

Gene therapy of thyroid carcinoma

ZHENG Wei,
TAN Jian

Department of Nuclear Medicine, Generd Hospital of Timjin Medical University, Tianjin 300652, China
CLC number: R730.54

摘要: 分化型甲状腺癌通常预后良好,但是对于约30%的低分化甲状腺癌,常规的治疗方法如"手术+¹³¹I治疗+甲状腺激素"的效果并不理想。国内外学者都在探索一种新的治疗策略——基因治疗。目前甲状腺癌的基因治疗策略主要有如下方面:(1)导入钠/碘同向转运体(NIS)基因,使本来不吸¹³¹I的癌细胞能够吸¹³¹I,从而采用放射性¹³¹I治疗;(2)增强机体抗肿瘤的免疫反应;(3)导入肿瘤细胞"自杀"基因;(4)抑制肿瘤细胞的生成;(5)抗血管生成基因治疗等。
- 甲状腺肿瘤 /
- 基因疗法 /
- 碘放射性同位素
Abstract: Normally, differentiated thyroid carcinoma(DTC) is a disease of good prognosis, but about 30% of the tumors are dedifferentiate, which are inaccessible to standard therapeutic procedures such as "operation ¹³¹I therapy mid thyroid hormone". Both internal and abroad experts are researching a new therapy of dedifferentiated thyroid carcinoma——gene therapy. Many of them utilize methods of it, but follow different strategies:(1) transduction of the thyroid sodium/iodide transporter gene to make tissues that do not accumulate iodide treatable by ¹³¹I therapy;(2) strengthening of the anti-tumor immune response;(3) suicide gene therapy;(4) depression the generation of tumor cells;(5) gene therapy of anti-vascularization.
- Thyroid neoplasm /
- Gene therapy /
- Iodine radioisotopes
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	余永利.不摄取¹³¹I的甲状腺癌治疗.国外医学·放射医学核医学分册,2005,29(2):57-63.
[2]	Bravo SB,Gacĺa-Rendueles MER,Seoane R,et al,Plitidepsin has a cytostatic effect in human undifferentiated(anaplastic) thyroid carcinoma.Clin Cancer Res,2005,11(21):7664-7673.
[3]	Cengic N,Bakw CH,Schütz M, et al.A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-apecific sodium iodide symporter gene expression.J Clin Endocrinol Metab,2005,90(8):4457-4464.
[4]	王深明,甲状腺癌的基因治疗.外科理论与实践,2003,8(4):286-288.
[5]	Kogai T,Tati K,Brent GA.Enhancement sodium/iodide symporter expression in thyroid,and breast cancer.Endocr Relat Cancer,2006,13(9):797-826.
[6]	Cho JY.A transporter gene(sodium iodide symporter) for dual purposes in gene therapy; imaging and therapy.Curr Gene Ther,2002,2(4):393-402.
[7]	Cho JY,Shen DH,Yang W, et al.In vivo imaging and:radioiodine therapy following sodium iodide symporter gens transfer in animal modeler of intracerebral glimas,Gene Ther,2002,9(17):1139-1145.
[8]	Shimura H,Haraguchi K,Miyazaki A,et al.Iodide uptake and experiment ¹³¹I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na⁺/I^- symporter gene.Endocrinology,1997,138(10):4493-4496.
[9]	Smit JW,Schroder-van der Elst JP,Karperien M,et al.Iodide kinetics and experimental ¹³¹I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line.J Clin Endocrinol Metab,2002,87(3):1247-1253.
[10]	Zhang R,Baunoch D,DeGroot LJ.Genetic immunotherapy for medullary thyroid carcinoma:destruction of tumors in mice by in vivo delivery of adenoviralvector transducing the murineinterleukin-2 gene.Thyroid,1998,8(12):1137-1146.
[11]	Zhang R,Straus FH,DeGroot LJ.Effective generic therapy of established medullary thyroid carcinomas with murine interleukin-2:dissemination and cytotoxicity studies in a rat tumor model.Endocrinology,1999,140(5):2152-2158.
[12]	Yamazaki M,Zhang R,Straus FH,et al Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12.Gene Ther,2002,9(1):64-74.
[13]	Soler MN,Bobe P,Benihoud K,et al.Gene therapy of rat medullary thyroid cancer by naked mitric oxide synthase II DNA injection.J Gene Med,2000,2(5):344-352.
[14]	Braiden V,Nagayama Y,Iitaka M,et al.Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter.Endocrinology,1998,139(9):3996-3999,.
[15]	Kitazono M,Chuman Y, Aikou T,et al.Adenovirus HSV-TK construct with thyroid-specific promoter:Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway.Int J Cancer,2002,99(3):453-459.
[16]	Zhang R,DeGroot LJ.Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model:relationship of bystander effect and antitumor efficacy.Thyroid,2000,10(4):313-319.
[17]	Zhang R,DeGToot LJ.An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma.Endocrine Related Cancer,2001,8(4):315-325.
[18]	Barzon L,Pacenti M,Taccaliti A,et al.A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma J Clin Endocrinol Metab,2005,90(5):2831-2834.
[19]	Ye CS,Feng G,Wang SM,et al.sFlt-1 gene therapy of follicular thyroid carcinoma.Endocrinology,2005,145(2):817-822.
[20]	DeGroot LJ,Zhang R.Clinical review 131:Gene therapy for thyroid cancer where do we stand?.J Clin Endocrinol Metab,2001,86(7):2923-2928.

[1]	郭睿 , 李彪 . 钠碘同向转运体基因介导放射性碘治疗肿瘤的研究进展. 国际放射医学核医学杂志, 2010, 34(3): 147-151. doi: 10.3760/cma.j.issn.1673-4114.2010.03.005
[2]	张俊 , 刘增礼 . 钠碘转运体基因介导的肿瘤放射性核素治疗研究. 国际放射医学核医学杂志, 2008, 32(1): 8-11.
[3]	翟红彦 , 苏成海 . 基因治疗联合放射治疗恶性肿瘤的分子机制. 国际放射医学核医学杂志, 2009, 33(2): 113-116. doi: 10.3760/cma.j.issn.1673-4114.2009.02.015
[4]	赵艳芝 , 李进 , 王芹 , 穆传杰 . 恶性肿瘤基因治疗和放射治疗相互作用的机制及联合治疗展望. 国际放射医学核医学杂志, 2006, 30(4): 250-253.
[5]	张耀文 , 曹永珍 , 李进 , 王芹 . 基因治疗联合放射治疗恶性肿瘤. 国际放射医学核医学杂志, 2008, 32(4): 247-250.
[6]	田玥 , 苏成海 . 恶性肿瘤的放射治疗联合基因治疗研究进展. 国际放射医学核医学杂志, 2008, 32(1): 43-46.
[7]	易艳玲 , 卓维海 . ¹³¹I治疗甲状腺肿瘤患者出院剂量指导水平分析. 国际放射医学核医学杂志, 2008, 32(6): 372-375.
[8]	刘建宇 , 朱宗平 , 石德道 , 郑飞波 . 放射性碘难治性分化型甲状腺癌去分化分子机制及再分化治疗的分子靶向药物. 国际放射医学核医学杂志, 2023, 47(2): 123-126. doi: 10.3760/cma.j.cn121381-202205003-00267
[9]	李宇轩 , 张禹 , 林志毅 , 苏耀东 , 石远颖 , 陈文新 . ⁹⁹Tc^m-3PRGD₂ SPECT/CT显像在不摄碘进展性放射性碘难治性分化型甲状腺癌中的诊断价值. 国际放射医学核医学杂志, 2023, 47(5): 281-288. doi: 10.3760/cma.j.cn121381-202301001-00304
[10]	冯成涛 , 张海波 , 郑皓 , 王梓延 , 邓赟 , 赵继华 , 朱高红 . ¹³¹I-PAMAM(G5.0)介导靶向肽在甲状腺髓样癌模型中的实验研究. 国际放射医学核医学杂志, 2019, 43(6): 528-537. doi: 10.3760/cma.j.issn.1673-4114.2019.06.007

点击查看大图

计量

文章访问数: 1508
HTML全文浏览量: 171
PDF下载量: 2

甲状腺癌的基因治疗

郑薇
谭建

300052 天津, 天津医科大学总医院核医学科

收稿日期: 2007-03-07

关键词:

摘要: 分化型甲状腺癌通常预后良好,但是对于约30%的低分化甲状腺癌,常规的治疗方法如"手术+¹³¹I治疗+甲状腺激素"的效果并不理想。国内外学者都在探索一种新的治疗策略——基因治疗。目前甲状腺癌的基因治疗策略主要有如下方面:(1)导入钠/碘同向转运体(NIS)基因,使本来不吸¹³¹I的癌细胞能够吸¹³¹I,从而采用放射性¹³¹I治疗;(2)增强机体抗肿瘤的免疫反应;(3)导入肿瘤细胞"自杀"基因;(4)抑制肿瘤细胞的生成;(5)抗血管生成基因治疗等。